Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Adipocyte fatty acid binding protein (A-FABP) as a potential new therapeutic target for treatment of obesity - associated cancers
Curr Drug Targets. 2021 Jul 12. doi: 10.2174/1389450122666210712193654. Online ahead of print.ABSTRACTFatty acid binding protein A (A-FABP) is one of FABPs isoforms found mainly in adipose tissue and macrophages. It works through many integrated pathways, regulating inflammation and lipid metabolism, promoting glucose production, impairing insulin function, and contributing to diseases such as atherosclerosis and diabetes. A-FABP is upregulated in the adipose tissue of obese patients and its increased release into the bloodstream is positively associated with body mass index. Consequently, A-FABP plays a key role in regula...
Source: Current Drug Targets - July 13, 2021 Category: Drugs & Pharmacology Authors: Kinga Majchrzak Marta Piotrowska Julia Krajewska Jakub Fichna Source Type: research

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707120256. Online ahead of print.ABSTRACTMonoamine oxidase (MAO) is an enzyme that catalyzes the deamination of monoamines and other proteins. MAO's hyperactivation results in the massive generation of reactive oxygen species, which leads to a variety of neurological diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and depression-like disorders. Although synthetic MAO inhibitors are clinically available, they are associated with side effects such as hepatotoxicity, cheese reaction, hypertensive crisis,...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Ashi Mannan Thakur Gurjeet Singh Varinder Singh Nikhil Garg Amarjot Kaur Manjinder Singh Source Type: research

Lipidomics As Tools For Finding Biomarkers Of Intestinal Pathology: From Irritable Bowel Syndrome To Colorectal Cancer
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707122151. Online ahead of print.ABSTRACTLipidomics is an emerging and promising branch that analyses the different lipid mole-cules in a biological sample. It is considered a branch of metabolomics, which is defined as the comprehensive analysis of metabolites in a biological specimen. Nonetheless, in recent years lipidomics is becoming a distinct discipline in the biomedicine field. Lipids play important roles in many biological pathways and can work as biomarkers of disease or therapeutic targets for the treatment of diseases. The major lipidomics strategies ar...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Lorena Ortega Moreno Pilar Navarro S ánchez Raquel Abalo Source Type: research

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707120256. Online ahead of print.ABSTRACTMonoamine oxidase (MAO) is an enzyme that catalyzes the deamination of monoamines and other proteins. MAO's hyperactivation results in the massive generation of reactive oxygen species, which leads to a variety of neurological diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and depression-like disorders. Although synthetic MAO inhibitors are clinically available, they are associated with side effects such as hepatotoxicity, cheese reaction, hypertensive crisis,...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Ashi Mannan Thakur Gurjeet Singh Varinder Singh Nikhil Garg Amarjot Kaur Manjinder Singh Source Type: research

Lipidomics As Tools For Finding Biomarkers Of Intestinal Pathology: From Irritable Bowel Syndrome To Colorectal Cancer
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707122151. Online ahead of print.ABSTRACTLipidomics is an emerging and promising branch that analyses the different lipid mole-cules in a biological sample. It is considered a branch of metabolomics, which is defined as the comprehensive analysis of metabolites in a biological specimen. Nonetheless, in recent years lipidomics is becoming a distinct discipline in the biomedicine field. Lipids play important roles in many biological pathways and can work as biomarkers of disease or therapeutic targets for the treatment of diseases. The major lipidomics strategies ar...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Lorena Ortega Moreno Pilar Navarro S ánchez Raquel Abalo Source Type: research

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707120256. Online ahead of print.ABSTRACTMonoamine oxidase (MAO) is an enzyme that catalyzes the deamination of monoamines and other proteins. MAO's hyperactivation results in the massive generation of reactive oxygen species, which leads to a variety of neurological diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and depression-like disorders. Although synthetic MAO inhibitors are clinically available, they are associated with side effects such as hepatotoxicity, cheese reaction, hypertensive crisis,...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Ashi Mannan Thakur Gurjeet Singh Varinder Singh Nikhil Garg Amarjot Kaur Manjinder Singh Source Type: research

Lipidomics As Tools For Finding Biomarkers Of Intestinal Pathology: From Irritable Bowel Syndrome To Colorectal Cancer
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707122151. Online ahead of print.ABSTRACTLipidomics is an emerging and promising branch that analyses the different lipid mole-cules in a biological sample. It is considered a branch of metabolomics, which is defined as the comprehensive analysis of metabolites in a biological specimen. Nonetheless, in recent years lipidomics is becoming a distinct discipline in the biomedicine field. Lipids play important roles in many biological pathways and can work as biomarkers of disease or therapeutic targets for the treatment of diseases. The major lipidomics strategies ar...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Lorena Ortega Moreno Pilar Navarro S ánchez Raquel Abalo Source Type: research

Insights into the Mechanism of the Therapeutic Potential of Herbal Monoamine Oxidase Inhibitors in Neurological Diseases
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707120256. Online ahead of print.ABSTRACTMonoamine oxidase (MAO) is an enzyme that catalyzes the deamination of monoamines and other proteins. MAO's hyperactivation results in the massive generation of reactive oxygen species, which leads to a variety of neurological diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, and depression-like disorders. Although synthetic MAO inhibitors are clinically available, they are associated with side effects such as hepatotoxicity, cheese reaction, hypertensive crisis,...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Ashi Mannan Thakur Gurjeet Singh Varinder Singh Nikhil Garg Amarjot Kaur Manjinder Singh Source Type: research

Lipidomics As Tools For Finding Biomarkers Of Intestinal Pathology: From Irritable Bowel Syndrome To Colorectal Cancer
Curr Drug Targets. 2021 Jul 7. doi: 10.2174/1389450122666210707122151. Online ahead of print.ABSTRACTLipidomics is an emerging and promising branch that analyses the different lipid mole-cules in a biological sample. It is considered a branch of metabolomics, which is defined as the comprehensive analysis of metabolites in a biological specimen. Nonetheless, in recent years lipidomics is becoming a distinct discipline in the biomedicine field. Lipids play important roles in many biological pathways and can work as biomarkers of disease or therapeutic targets for the treatment of diseases. The major lipidomics strategies ar...
Source: Current Drug Targets - July 9, 2021 Category: Drugs & Pharmacology Authors: Lorena Ortega Moreno Pilar Navarro S ánchez Raquel Abalo Source Type: research

Corrigendum to: Can Medical Therapy Fix Sexual Dysfunction after Major Pelvic and Prostate Surgery and does it Work for Kidney Stones? Chemotherapy before Cystectomy, New Schemes for which Patients?
Curr Drug Targets. 2021;22(9):1087. doi: 10.2174/138945012209210609101710.ABSTRACTDue to an editorial oversight, we would like to apologize for an error that occurred in the both print and online version of an editorial entitled "Can Medical Therapy Fix Sexual Dysfunction after Major Pelvic and Prostate Surgery and does it Work for Kidney Stones? Chemotherapy before Cystectomy, New Schemes for which Patients?. It was published without the co-authors' names in the journal "Current Drug Targets" 2021; 22(1): 2 [1]. The original editorial can be found online at https://doi.org/10.2174/138945012201201231123209 R...
Source: Current Drug Targets - July 7, 2021 Category: Drugs & Pharmacology Authors: Petros Sountoulides Ioannis Mykoniatis Ioannis Vakalopoulos Luca Cindolo Source Type: research

Corrigendum to: Can Medical Therapy Fix Sexual Dysfunction after Major Pelvic and Prostate Surgery and does it Work for Kidney Stones? Chemotherapy before Cystectomy, New Schemes for which Patients?
Curr Drug Targets. 2021;22(9):1087. doi: 10.2174/138945012209210609101710.ABSTRACTDue to an editorial oversight, we would like to apologize for an error that occurred in the both print and online version of an editorial entitled "Can Medical Therapy Fix Sexual Dysfunction after Major Pelvic and Prostate Surgery and does it Work for Kidney Stones? Chemotherapy before Cystectomy, New Schemes for which Patients?. It was published without the co-authors' names in the journal "Current Drug Targets" 2021; 22(1): 2 [1]. The original editorial can be found online at https://doi.org/10.2174/138945012201201231123209 R...
Source: Current Drug Targets - July 7, 2021 Category: Drugs & Pharmacology Authors: Petros Sountoulides Ioannis Mykoniatis Ioannis Vakalopoulos Luca Cindolo Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Parkinson's disease: A current perspectives on Parkinson's disease and key bioactive natural compounds as future potential drug candidates
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623115505. Online ahead of print.ABSTRACTParkinson's disease (PD) is one of the most common types of neurological disorder prevailing worldwide and is rapidly increasing in the elderly population across the globe. The cause of PD is still unknown, but a number of genetic as well as environmental factors contributing to the pathogenesis of Parkinson's disease have been identified. The hallmark of PD includes dopamine deficiency (neurotransmitter imbalance) due to the gradual loss of dopaminergic nerves in the substantia nigra in the midbrain. Studying the mutation...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Nabeel Ali Amna Syeda Tenzin Topgyal Naseem Gaur Asimul Islam Source Type: research

Gut Microbiota And Inflammatory Disorders
Curr Drug Targets. 2021 Jun 23. doi: 10.2174/1389450122666210623125603. Online ahead of print.ABSTRACTThe gut has been colonized with bacteria, fungi, viruses, archaea, eukarya. The human and bacterial cells are found in a 1:1 ratio, while the variance in the diversity of gut microbiota may result in Dysbiosis. Gut dysbiosis may result in various pathological manifestations. Beneficial gut microbiota may synthesize short-chain fatty acids like acetate, butyrate, propionate, while -gram-negative organisms are the primary source of LPS, a potent pro-inflammatory mediator. Both gut microbiota and microbial products may be inv...
Source: Current Drug Targets - June 24, 2021 Category: Drugs & Pharmacology Authors: Vamsi Korlepara Naveen Kumar Sugato Banerjee Source Type: research

Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer
Curr Drug Targets. 2021 Jun 17. doi: 10.2174/1389450122666210617111304. Online ahead of print.ABSTRACTEndometrial cancer is one of the three most common malignant tumors in the female reproductive system. Advanced and recurrent endometrial cancers have poor prognoses and lack effective treatments. Poly(ADP-ribose) polymerase (PARP) inhibitors have been applied to many different types of tumors, and they can selectively kill tumor cells that are defective in homologous recombination repair. Endometrial cancer is characterized by mutations in homologous recombination repair genes; accordingly, PARP inhibitors have achieved p...
Source: Current Drug Targets - June 18, 2021 Category: Drugs & Pharmacology Authors: Ke Shen Li Yang Fei-Yan Li Feng Zhang Lei-Lei Ding Jing Yang Jie Lu Nan-Nan Wang Yan Wang Source Type: research

Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer
Curr Drug Targets. 2021 Jun 17. doi: 10.2174/1389450122666210617111304. Online ahead of print.ABSTRACTEndometrial cancer is one of the three most common malignant tumors in the female reproductive system. Advanced and recurrent endometrial cancers have poor prognoses and lack effective treatments. Poly(ADP-ribose) polymerase (PARP) inhibitors have been applied to many different types of tumors, and they can selectively kill tumor cells that are defective in homologous recombination repair. Endometrial cancer is characterized by mutations in homologous recombination repair genes; accordingly, PARP inhibitors have achieved p...
Source: Current Drug Targets - June 18, 2021 Category: Drugs & Pharmacology Authors: Ke Shen Li Yang Fei-Yan Li Feng Zhang Lei-Lei Ding Jing Yang Jie Lu Nan-Nan Wang Yan Wang Source Type: research

Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer
Curr Drug Targets. 2021 Jun 17. doi: 10.2174/1389450122666210617111304. Online ahead of print.ABSTRACTEndometrial cancer is one of the three most common malignant tumors in the female reproductive system. Advanced and recurrent endometrial cancers have poor prognoses and lack effective treatments. Poly(ADP-ribose) polymerase (PARP) inhibitors have been applied to many different types of tumors, and they can selectively kill tumor cells that are defective in homologous recombination repair. Endometrial cancer is characterized by mutations in homologous recombination repair genes; accordingly, PARP inhibitors have achieved p...
Source: Current Drug Targets - June 18, 2021 Category: Drugs & Pharmacology Authors: Ke Shen Li Yang Fei-Yan Li Feng Zhang Lei-Lei Ding Jing Yang Jie Lu Nan-Nan Wang Yan Wang Source Type: research

Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer
Curr Drug Targets. 2021 Jun 17. doi: 10.2174/1389450122666210617111304. Online ahead of print.ABSTRACTEndometrial cancer is one of the three most common malignant tumors in the female reproductive system. Advanced and recurrent endometrial cancers have poor prognoses and lack effective treatments. Poly(ADP-ribose) polymerase (PARP) inhibitors have been applied to many different types of tumors, and they can selectively kill tumor cells that are defective in homologous recombination repair. Endometrial cancer is characterized by mutations in homologous recombination repair genes; accordingly, PARP inhibitors have achieved p...
Source: Current Drug Targets - June 18, 2021 Category: Drugs & Pharmacology Authors: Ke Shen Li Yang Fei-Yan Li Feng Zhang Lei-Lei Ding Jing Yang Jie Lu Nan-Nan Wang Yan Wang Source Type: research

Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer
Curr Drug Targets. 2021 Jun 17. doi: 10.2174/1389450122666210617111304. Online ahead of print.ABSTRACTEndometrial cancer is one of the three most common malignant tumors in the female reproductive system. Advanced and recurrent endometrial cancers have poor prognoses and lack effective treatments. Poly(ADP-ribose) polymerase (PARP) inhibitors have been applied to many different types of tumors, and they can selectively kill tumor cells that are defective in homologous recombination repair. Endometrial cancer is characterized by mutations in homologous recombination repair genes; accordingly, PARP inhibitors have achieved p...
Source: Current Drug Targets - June 18, 2021 Category: Drugs & Pharmacology Authors: Ke Shen Li Yang Fei-Yan Li Feng Zhang Lei-Lei Ding Jing Yang Jie Lu Nan-Nan Wang Yan Wang Source Type: research

The In Vivo Fate and Strategies of Improving the Targeting Effect of Nanoparticles
Curr Drug Targets. 2021;22(8):844. doi: 10.2174/138945012208210407114925.NO ABSTRACTPMID:34112065 | DOI:10.2174/138945012208210407114925 (Source: Current Drug Targets)
Source: Current Drug Targets - June 11, 2021 Category: Drugs & Pharmacology Authors: Jihui Tang Jianping Zhou Source Type: research

The In Vivo Fate and Strategies of Improving the Targeting Effect of Nanoparticles
Curr Drug Targets. 2021;22(8):844. doi: 10.2174/138945012208210407114925.NO ABSTRACTPMID:34112065 | DOI:10.2174/138945012208210407114925 (Source: Current Drug Targets)
Source: Current Drug Targets - June 11, 2021 Category: Drugs & Pharmacology Authors: Jihui Tang Jianping Zhou Source Type: research

The In Vivo Fate and Strategies of Improving the Targeting Effect of Nanoparticles
Curr Drug Targets. 2021;22(8):844. doi: 10.2174/138945012208210407114925.NO ABSTRACTPMID:34112065 | DOI:10.2174/138945012208210407114925 (Source: Current Drug Targets)
Source: Current Drug Targets - June 11, 2021 Category: Drugs & Pharmacology Authors: Jihui Tang Jianping Zhou Source Type: research

The In Vivo Fate and Strategies of Improving the Targeting Effect of Nanoparticles
Curr Drug Targets. 2021;22(8):844. doi: 10.2174/138945012208210407114925.NO ABSTRACTPMID:34112065 | DOI:10.2174/138945012208210407114925 (Source: Current Drug Targets)
Source: Current Drug Targets - June 11, 2021 Category: Drugs & Pharmacology Authors: Jihui Tang Jianping Zhou Source Type: research